title: Cholesterol metabolism in patients with chronic renal failure on hemodialysis.
abstract: Premature atherosclerosis is a major concern in patients on chronic dialysis and the identification of risk factors is important for preventive and interventional strategies. Other than the recognized atherogenic lipoprotein levels, little is known about overall cholesterol metabolism in patients on chronic hemodialysis (HD) and the best therapeutic intervention is still being debated. Therefore, we investigated intestinal cholesterol absorption, cholesterol and bile acid synthesis, and non-cholesterol plasma sterols in eight patients on dialysis and compared the results to those of 16 healthy male controls matched for body mass index and dietary cholesterol intake. Total, low-density lipoprotein (LDL) cholesterol, and triglycerides did not differ between the groups, but dialysis patients had a significantly lower high-density lipoprotein (HDL) cholesterol level (39 +/- 11 mg/dL vs. 48 +/- 10 mg/dL, p < 0.045). However, fractional cholesterol absorption, was significantly lower in dialysis patients (42.8 +/- 10.9% vs. 53.4 +/- 11%, p < 0.035), whereas plasma plant sterol concentrations and their ratios to cholesterol did not differ. Bile acid and total cholesterol synthesis were lower in dialysis patients (40% and -25%, respectively), although the differences were not significant. In contrast, lathosterol and its ratio to cholesterol in plasma was significantly lower in dialysis patients (0.176 +/- 0.084 mg/dL vs. 0.251 +/- 0.102 mg/dL, p < 0.024 and 0.733 +/- 0.353 microg/mg vs. 1.172 +/- 0.407 microg/mg, p < 0.017, respectively), indicating reduced hepatic de novo cholesterol synthesis. It is concluded that reduced HDL cholesterol and reduced bile acid synthesis contributes to atherosclerosis pathogenesis in dialysis patients, whereas intestinal cholesterol absorption and hepatic cholesterol synthesis did not seem dominant in this process at this stage of disease. Consequently, treatment with bile acid binding resins could be preferable to treatment with cholesterol absorption and synthesis inhibitors.
authors.affiliation: Department of Clinical Pharmacology, University of Bonn, Bonn, Germany.
authors.forename: Arina
authors.initials: A
authors.lastname: Igel-Korcagova
authors.forename: Peter
authors.initials: P
authors.lastname: Raab
authors.forename: Karl August
authors.initials: KA
authors.lastname: Brensing
authors.forename: Uwe
authors.initials: U
authors.lastname: Pöge
authors.forename: Hans-Ulrich
authors.initials: HU
authors.lastname: Klehr
authors.forename: Michael
authors.initials: M
authors.lastname: Igel
authors.forename: Klaus
authors.initials: K
authors.lastname: von Bergmann
authors.forename: Thomas
authors.initials: T
authors.lastname: Sudhop
mesh_terms: D000328:Adult; D001647:Bile Acids and Salts / Q000096:biosynthesis; D002784:Cholesterol / Q000378:metabolism*; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010840:Phytosterols / Q000097:blood; D006435:Renal Dialysis; D014280:Triglycerides / Q000097:blood
chemical_list: D001647:Bile Acids and Salts; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D010840:Phytosterols; D014280:Triglycerides; D002784:Cholesterol